Drug Profile
EP 400
Alternative Names: EP-400Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator EpiThany; University of Washington
- Class Antigens; Vaccines
- Mechanism of Action Th1 cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 09 Jun 2023 Discontinued - Preclinical for Colorectal cancer in USA (Parenteral) before June 2023 (EpiThany pipeline, June 2023)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Colorectal-cancer in USA (Parenteral)
- 05 Oct 2016 Preclinical trials in Colorectal cancer in USA (Parenteral) (EpiThany pipeline, October 2016)